Frontlight ResearchEarly access
Type 2 diabetes trials in United Kingdom
42 of 62 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Where
- Birmingham, Blackburn, Bournemouth, Bradford, Bristol, Bromborough, Chichester, Cosham, Darlington, Derby, Dundee, Falmouth, Guisborough, Ipswich, Kirkcaldy, Lancaster, Leeds, Lincoln, London, Manchester, Middlesbrough, Newcastle upon Tyne, Northallerton, Norwich, Southampton, Swansea, Trowbridge, Weymouth, York
- Age
- 18 years and over
- People
- 11,800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07064473 · EU 2025-521188-11-00 - Phase 3Not yet taking people in United KingdomAMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
- Where
- Blackburn, Bushey, Chippenham, Liskeard, London, Nantwich, Rotherham, Sandbach, Swansea, Torquay, Truro
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07931573 · EU 2026-525472-26-00 - Phase 3Not yet taking people in United KingdomA Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
- Where
- Blackburn, London, Nantwich, Rotherham, Sandbach, Swansea, Truro, Wellingborough
- Age
- 18 years and over
- People
- 1,060 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07931599 · EU 2026-525474-20-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Where
- Airdrie, Birmingham, Chippenham, Glasgow, Leicester, London, Newcastle upon Tyne, Soham, Swansea
- Age
- 18 years and over
- People
- 2,000 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07351045 · EU 2025-523104-71-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Where
- Aberdeen, Antrim, Blackpool, Bristol, Dundee, Hounslow, Hull, Nuneaton, Plymouth, Taunton
- Age
- 18 years and over
- People
- 1,600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07351058 · EU 2025-523106-32-00 - Phase 3Taking peopleA Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Where
- Airdrie, Chippenham, Hull, Llandough, Rotherham
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07776509 · EU 2025-523295-23-00 - Phase 3Taking peopleA Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
- Where
- Hull, Liverpool, London
- Age
- 10 years to 17 years
- People
- 170 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07668336 · EU 2025-524811-35-00 - Phase 2Taking peopleA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Where
- Birmingham, Blackpool, Bristol, Bromborough, Newcastle, Newquay, Nuneaton, Poole, Rotherham, Torpoint
- Age
- 18 years to 75 years
- People
- 200 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06897475 · EU 2024-520328-27-00 - Phase 3Not yet taking people in United KingdomA Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
- Where
- Blackpool, Lancashire, London, Penzance, Romsey, West Kirby
- Age
- 18 years and over
- People
- 2,115 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07881432 · EU 2026-526047-34-00 - Phase 3Taking peopleA Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- Where
- Blackburn, Dundee, Guisborough, Nantwich, Rotherham, Thetford, Weston-super-Mare, Witney, Woodbridge, Yate
- Age
- 18 years and over
- People
- 2,000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07662109 · EU 2025-523941-81-00 - Phase 3Taking peopleA Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Where
- Chippenham, Corby, Dunfermline, Hull, Northwood
- Age
- 18 years and over
- People
- 1,500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07784270 - No phaseTaking peopleGLycaemic Outcomes With Whey Protein in ageING
- Where
- Birmingham
- Age
- 70 years to 90 years
- People
- 32
- Run by
- University of Birmingham
See details and how to joinNCT07285811 - Phase 3Taking peopleA Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Where
- Aberdeen, Addlestone, Banbury, Bristol, Edinburgh, Hounslow, Penzance, Poole, Soham, Wansford, Yate
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07662213 · EU 2025-523933-24-00 - No phaseTaking peopleA Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing Haemodialysis
- Where
- Derby, London, Manchester
- Age
- 18 years and over
- People
- 84
- Run by
- Imperial College London
See details and how to joinNCT07422532 - Phase 3Taking peopleKHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
- Where
- London
- Age
- 18 years to 64 years
- People
- 220 worldwide
- Run by
- Khondrion BV
See details and how to joinNCT06451757 · EU 2025-522361-30-00 - Phase 3Taking peopleA Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
- Where
- Ashton-under-Lyne, Blackpool, Chesterfield, Corby, Ely, Glasgow, Hounslow, Leicester, Metropolitan Borough of Wirral, Nantwich, Poole, Rotherham, Stowmarket, Wansford, Witney, Yate
- Age
- 18 years and over
- People
- 4,500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07667803 - Phase 3Taking peopleExtension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Where
- Birmingham
- Age
- 18 years to 99 years
- People
- 950 worldwide
- Run by
- Amgen
See details and how to joinNCT07684144 · EU 2025-524788-19-00 - No phaseTaking peopleSurveillance of Pancreatic Health After Diabetes Diagnosis
- Where
- Ashton-under-Lyne, Birmingham, Bournemouth, Brockham, Bromborough, Burton-on-Trent, Epsom, Kibworth Beauchamp, Kingswinford, Leek, Leicester, London, Maidstone, Manchester, Nottingham, Portsmouth, Rossendale, Ruislip, Sandbach, Southampton, Stratford-upon-Avon, Uttoxeter, Uxbridge, Walsall, Warlingham, Weymouth
- Age
- 50 years to 84 years
- People
- 5,000
- Run by
- University Hospital Southampton NHS Foundation Trust
See details and how to joinNCT06803771 - Phase 3Taking peopleA Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Where
- Blackpool, Bradford on Avon, Lancashire, Lancaster, Londonderry, Manchester, Peterborough, Romsey, Torpoint
- Age
- 18 years and over
- People
- 1,980 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07321886 · EU 2025-523657-34-00 - Phase 3Not yet taking people in United KingdomA Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- Where
- Cardiff, Edgbaston, Glasgow, London, Manchester, Stoke-on-Trent, Warrington
- Age
- 18 years and over
- People
- 1,560 worldwide
- Run by
- Ascletis Pharma (China) Co., Limited
See details and how to joinNCT07743450 - Phase 4Taking peopleA Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
- Where
- Altrincham, Ashton-under-Lyne, Bolton, Bury, Cheshire, Great Lever, Hyde SK14, Manchester, Oldham, Rochdale, Sale, Salford, Stockport, Swinton, Wigen
- Age
- 18 years and over
- People
- 3,000
- Run by
- Eli Lilly and Company
See details and how to joinNCT07247084 - Phase 3Taking peopleA Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
- Where
- Blackpool, Glasgow, Hull, Penzance, Sandbach, Thetford, Whitney
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07662135 · EU 2025-523940-12-00 - Phase 3Taking peopleA Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
- Where
- Edinburgh, Headington, London, Newcastle upon Tyne
- Age
- 18 years to 65 years
- People
- 57 worldwide
- Run by
- Vertex Pharmaceuticals Incorporated
See details and how to joinNCT04786262 · EU 2024-513929-23-00 - No phaseEnrolling by invitationFree Fatty Acid Effects In Type 2 Diabetes
- Where
- Coleraine
- Age
- 18 years and over
- People
- 60
- Run by
- University of Ulster
See details and how to joinNCT07677995 - Phase 3Not yet taking people in United KingdomAMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- Where
- Bristol, Coventry, Hull, Ipswich, Londonderry, Newquay, Rotherham, Swansea, Wallasey, Yeovil
- Age
- 45 years and over
- People
- 1,778 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07797335